Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

ZacksResearch Sep. 12 at 1:47 PM

$CRL shares have risen 5.2% in the past three months, outpacing an industry decline of 3.4%! 🚀 Charles River's strategic partnerships in oncology and cell therapy are driving positive market sentiment. With a Zacks Rank #2 and a favorable 6.19% earnings yield, this stock is showing strong potential. Discover more about CRL's growth strategies here 👉 https://www.zacks.com/stock/news/2750567/crl-stock-rises-following-new-strategic-oncology-collaborations?cid=sm-stocktwits-2-2750567-body-12159&ADID=SYND_STOCKTWITS_TWEET_2_2750567_BODY_12159

0 · Reply

ZacksResearch Sep. 12 at 12:47 PM

$CRL surges on fresh oncology momentum 🚀 New collaborations with PICI and CHLA are strengthening its oncology and cell therapy pipeline, fueling investor optimism. See what’s driving $CRL higher 👉 https://www.zacks.com/stock/news/2750567/crl-stock-rises-following-new-strategic-oncology-collaborations?cid=sm-stocktwits-2-2750567-teaser-12157&ADID=SYND_STOCKTWITS_TWEET_2_2750567_TEASER_12157

0 · Reply

topstockalerts Sep. 9 at 7:29 PM

Jefferies upgraded IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. IQVIA was named top pick, with stronger client wins, stable trends, and less reliance on single customers; price target raised to $225. ICON faces client losses, project cancellations near $ 1B in Q3, and biotech weakness, leading to a price target cut to $175. Charles River gained on stronger bookings, safety-testing demand, and potential value from a manufacturing unit sale, with a $195 target. Jefferies stayed cautious on Medpace (valuation) and Fortrea (execution risks). $IQV $CRL $ICLR $ICON

1 · Reply

JarvisFlow Sep. 9 at 11:00 AM

Jefferies has updated their rating for Charles River ( $CRL ) to Buy with a price target of 195.

0 · Reply

StockAutoPro Sep. 4 at 2:56 PM

$CRL: Buy target $155.66 Sell target $165.54 Strong earnings growth potential makes this biotech firm a solid long-term investment in the CRL sector.

0 · Reply

ZacksResearch Sep. 4 at 2:11 PM

Is $CRL poised for a comeback? 📈 Despite a 15.4% drop over the past year, Charles River's DSA segment shows promise with strategic acquisitions like Noveprim and SAMDI Tech fueling growth. However, macroeconomic conditions and currency fluctuations remain concerns for its operations. Discover the full growth narrative here 👉 https://www.zacks.com/stock/news/2747092/is-it-the-right-time-to-add-crl-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2747092-body-10885&ADID=SYND_STOCKTWITS_TWEET_2_2747092_BODY_10885

0 · Reply

ZacksResearch Sep. 4 at 12:44 PM

Is $CRL finally a buy? 🧐 The stock is under the spotlight as investors weigh whether current conditions make it the right time to add shares to their portfolios. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2747092/is-it-the-right-time-to-add-crl-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2747092-teaser-10863&ADID=SYND_STOCKTWITS_TWEET_2_2747092_TEASER_10863

0 · Reply

StockAutoPro Sep. 4 at 4:13 AM

$CRL: Buy target $160.33 Sell target $170.45 Strong earnings growth indicates potential investment opportunity in this leading clinical research organization.

0 · Reply

StockAutoPro Sep. 3 at 1:48 PM

$CRL: Buy target $159.25 Sell target $169.31 Strong Q2 earnings report indicates potential for significant growth in the CRL sector leader.

0 · Reply

StockAutoPro Sep. 3 at 3:21 AM

$CRL: Buy target $159.25 Sell target $169.31 Rising research demand indicates potential growth in leading CRL sector company.

0 · Reply

Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

Sep 10, 2025, 12:40 PM EDT - 4 days ago

Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 9, 2025, 1:09 PM EDT - 5 days ago

Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:00 AM EDT - 6 days ago

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Sep 3, 2025, 8:00 AM EDT - 11 days ago

Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences

Aug 26, 2025, 8:00 AM EDT - 19 days ago

Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing

Aug 6, 2025, 1:30 PM EDT - 5 weeks ago

Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:50 PM EDT - 5 weeks ago

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Aug 6, 2025, 12:47 PM EDT - 5 weeks ago

Charles River: Margin Fears Outweigh Solid Q2

Aug 6, 2025, 7:55 AM EDT - 5 weeks ago

Charles River raises profit forecast on growing demand for drug development services

Aug 6, 2025, 7:00 AM EDT - 5 weeks ago

Charles River Laboratories Announces Second-Quarter 2025 Results

Jul 22, 2025, 8:00 AM EDT - 7 weeks ago

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 2 months ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

May 28, 2025, 8:00 AM EDT - 3 months ago

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

May 13, 2025, 8:00 AM EDT - 4 months ago

Charles River Laboratories to Present at Bank of America Health Care Conference

May 10, 2025, 8:49 AM EDT - 4 months ago

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

May 7, 2025, 5:31 PM EDT - 4 months ago

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

May 7, 2025, 2:46 PM EDT - 4 months ago

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:39 PM EDT - 4 months ago

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

May 7, 2025, 12:17 PM EDT - 4 months ago

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

May 7, 2025, 11:56 AM EDT - 4 months ago

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

DIS SMCI

May 7, 2025, 7:35 AM EDT - 4 months ago

Charles River to add new directors, review business in agreement with Elliott

May 7, 2025, 7:01 AM EDT - 4 months ago

Charles River Laboratories Announces First-Quarter 2025 Results

May 7, 2025, 7:00 AM EDT - 4 months ago

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

May 7, 2025, 6:08 AM EDT - 4 months ago

Exclusive: Charles River agrees with Elliott to add new directors, review business

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

Apr 22, 2025, 8:00 AM EDT - 5 months ago

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

Apr 15, 2025, 4:30 PM EDT - 5 months ago

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Apr 11, 2025, 10:44 AM EDT - 5 months ago

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

CERT SLP

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Mar 4, 2025, 4:05 AM EST - 6 months ago

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

Feb 25, 2025, 8:00 AM EST - 7 months ago

Charles River Announces Agreement with Singapore General Hospital

Feb 19, 2025, 4:58 PM EST - 7 months ago

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Feb 19, 2025, 3:03 PM EST - 7 months ago

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:11 AM EST - 7 months ago

Charles River beats quarterly estimates on stable demand for drug development services

Feb 19, 2025, 7:00 AM EST - 7 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Feb 11, 2025, 8:00 AM EST - 7 months ago

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Jan 28, 2025, 4:30 PM EST - 8 months ago

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Jan 21, 2025, 8:00 AM EST - 8 months ago

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Jan 16, 2025, 8:00 AM EST - 8 months ago

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Jan 13, 2025, 8:00 AM EST - 8 months ago

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 8 months ago

Deciphex Secures $32.3M Series C to Address Global Pathology Shortage

Dec 20, 2024, 7:51 AM EST - 9 months ago

Tax-related selling is hitting these 7 stocks — but their loss could be your gain

AVNW CVS DLHC FL VAL

Dec 5, 2024, 8:00 AM EST - 10 months ago

Charles River Introduces Global Biotech Incubator Program

Dec 2, 2024, 8:00 AM EST - 10 months ago

Charles River Laboratories to Present at Evercore ISI Investor Conference

Nov 11, 2024, 8:00 AM EST - 10 months ago

Charles River Laboratories to Present at UBS and Jefferies Conferences

Nov 6, 2024, 6:51 PM EST - 11 months ago

Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript

ZacksResearch Sep. 12 at 1:47 PM

0 · Reply

ZacksResearch Sep. 12 at 12:47 PM

0 · Reply

topstockalerts Sep. 9 at 7:29 PM

1 · Reply

JarvisFlow Sep. 9 at 11:00 AM

Jefferies has updated their rating for Charles River ( $CRL ) to Buy with a price target of 195.

0 · Reply

StockAutoPro Sep. 4 at 2:56 PM

$CRL: Buy target $155.66 Sell target $165.54 Strong earnings growth potential makes this biotech firm a solid long-term investment in the CRL sector.

0 · Reply

ZacksResearch Sep. 4 at 2:11 PM

0 · Reply

ZacksResearch Sep. 4 at 12:44 PM

0 · Reply

StockAutoPro Sep. 4 at 4:13 AM

$CRL: Buy target $160.33 Sell target $170.45 Strong earnings growth indicates potential investment opportunity in this leading clinical research organization.

0 · Reply

StockAutoPro Sep. 3 at 1:48 PM

$CRL: Buy target $159.25 Sell target $169.31 Strong Q2 earnings report indicates potential for significant growth in the CRL sector leader.

0 · Reply

StockAutoPro Sep. 3 at 3:21 AM

$CRL: Buy target $159.25 Sell target $169.31 Rising research demand indicates potential growth in leading CRL sector company.

0 · Reply

StockAutoPro Aug. 29 at 4:29 PM

$CRL: Buy target $161.9 Sell target $172.09 Strong performance in the testing services segment could boost CRL sector stock growth.

0 · Reply

smartkarma Aug. 25 at 6:03 AM

$CRL | Charles River Laboratories: Initiation of Coverage- Leveraging Regulatory Wins – Will Flexibility Cement Its Market Leadership? "Charles River Laboratories delivered a mixed financial performance in the second quarter of 2025, presenting some positive aspects alongside key..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/charles-river-laboratories-initiation-of-coverage-leveraging-regulatory-wins-will-flexibility-cement-its-market-leadership

0 · Reply

StockAutoPro Aug. 24 at 11:14 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings report suggests potential for continued growth in leading CRL sector company.

0 · Reply

StockAutoPro Aug. 24 at 3:46 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings growth potential in the clinical research sector signals a bullish outlook.

0 · Reply

GhostVertex Aug. 23 at 10:16 AM

$CRL Charles River Laboratories International Inc is facing biopharma funding environment challenges

0 · Reply

RunnerSignals Aug. 23 at 5:53 AM

$BCPC $CFR $CNQ $CRL $EFX all pushed above their 200DMA today. Some steady, some gaining steam worth watching if momentum holds https://stocksrunner.com/news/2025-08-22-advanced-technical-analysis-for-stock-trading-strategies

0 · Reply

CycleTrade Aug. 22 at 7:12 PM

$CRL Charles Iver Labs support at 100EMA and set for swing https://www.tradingview.com/x/tU7nxO7n/

0 · Reply

StockAutoPro Aug. 21 at 2:41 PM

$CRL: Buy target $157.58 Sell target $167.56 Expect increased volatility in the clinical research sector due to pending healthcare policy changes.

0 · Reply

StockAutoPro Aug. 13 at 11:29 PM

$CRL: Buy target $153.0 Sell target $162.75 Consider investing in this leading contract research organization, showing consistent growth and strong future prospects.

0 · Reply

StockAutoPro Aug. 11 at 8:37 PM

$CRL: Buy target $146.44 Sell target $155.86 Rising demand for telehealth services could boost this leading digital healthcare provider's stock value.

0 · Reply

JarvisFlow Aug. 8 at 12:31 PM

Evercore ISI Group updates rating for Charles River ( $CRL ) to Outperform, target set at 180 → 190.

0 · Reply

JarvisFlow Aug. 7 at 7:10 PM

JP Morgan has updated their rating for Charles River ( $CRL ) to Neutral with a price target of 160.

0 · Reply

Market Cap	7.52B
Revenue (ttm)	4.05B
Net Income (ttm)	22.20M
EPS (ttm)	N/A
PE Ratio	14.91
Forward PE	15.67
Profit Margin	0.55%
Debt to Equity Ratio	0.69

Volume	768,700
Avg Vol	869,010
Day's Range	N/A - N/A
Shares Out	49.21M
Stochastic %K	21%
Beta	1.47
Analysts	Sell
Price Target	$174.00